- Home
- GAU vs ACHV Comparison
GAU vs ACHV Comparison
Compare GAU & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAU | ACHV |
|---|---|---|
| Founded | 1999 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 627.8M | 726.5M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GAU | ACHV |
|---|---|---|
| Price | $1.96 | $7.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.08 | ★ $14.67 |
| AVG Volume (30 Days) | ★ 2.4M | 1.5M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $82.77 | N/A |
| Revenue Next Year | $29.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $2.62 |
| 52 Week High | $3.62 | $8.64 |
Technical Indicators
Market Signals| Indicator | GAU | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 39.93 | 47.69 |
| Support Level | $1.70 | $7.01 |
| Resistance Level | $2.01 | $8.63 |
| Average True Range (ATR) | 0.08 | 0.37 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 8.97 | 37.59 |
Price Performance
Historical ComparisonAbout GAU Galiano Gold Inc.
Galiano Gold Inc is focused on building a sustainable business capable of long term value creation for its stakeholders through a combination of exploration, accretive acquisitions, and disciplined deployment of its financial resources. The company currently operates and manages: Nkran, Esaase, Abore and Miradani North, multiple satellite deposits and exploration projects located on the Asankrangwa Gold Belt in the Amansie West District of the Republic of Ghana (Ghana), West Africa.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.